Asenapine

Drug Profile

Asenapine

Alternative Names: Asenapine maleate; Atisenap; ME2136; ORG-5222; Saphris; SCH-900274; Sycrest

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Allergan; Lundbeck A/S; Meiji Seika Pharma; Merck & Co
  • Class Antipsychotics; Heterocyclic compounds with 4 or more rings; Oxepins; Pyrrolidines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists; Dopamine receptor antagonists; Histamine H1 receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia

Most Recent Events

  • 20 Jul 2017 Merck terminates a phase II trial as the funding ended due to recruitment delays for Bipolar disorders in USA (PO) (NCT01807741)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In children) in USA (Sublingual, Tablet)
  • 17 Jul 2015 Launched for Bipolar disorders (In adolescents, In children) in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top